Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Assets: 2020-2025

Historic Other Non-Current Assets for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $1.5 million.

  • Insight Molecular Diagnostics' Other Non-Current Assets fell 11.76% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 11.76%. This contributed to the annual value of $1.7 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Other Non-Current Assets stood at $1.5 million, which was down 11.76% from $1.7 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Other Non-Current Assets high stood at $29.7 million for Q4 2021, and its period low was $1.5 million during Q3 2025.
  • Moreover, its 3-year median value for Other Non-Current Assets was $1.7 million (2025), whereas its average is $1.7 million.
  • In the last 5 years, Insight Molecular Diagnostics' Other Non-Current Assets surged by 1,646.00% in 2021 and then crashed by 92.85% in 2022.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Other Non-Current Assets stood at $29.7 million in 2021, then crashed by 92.85% to $2.1 million in 2022, then declined by 19.85% to $1.7 million in 2023, then remained steady at $1.7 million in 2024, then declined by 11.76% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.7 million for Q2 2025, and $1.7 million during Q1 2025.